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There has been a sharp rise in the occurrence of Candida infections and associated
mortality over the last few years, due to the growing body of immunocompromised
population. Limited number of currently available antifungal agents, undesirable side
effects and toxicity, as well as emergence of resistant strains pose a considerable
clinical challenge for the treatment of candidiasis. Therefore, molecules that derived from
natural sources exhibiting considerable antifungal properties are a promising source for
the development of novel anti-candidal therapy. Phenolic compounds isolated from
natural sources possess antifungal properties of interest. Particularly, phenolic acids
have shown promising in vitro and in vivo activity against Candida species. However,
studies on their mechanism of action alone or in synergism with known antifungals are
still scarce. This review attempts to discuss the potential use, proposed mechanisms of
action and limitations of the phenolic acids in anti-candidal therapy.
Keywords: Candida, phenolic acids, phenolic compounds, antifungal effect, synergism
INTRODUCTION
Candida species are a major group of fungal pathogens in humans, particularly among
immunocompromised and hospitalized patients (Cuellar-Cruz et al., 2012). Candida albicans
inhabits various body surfaces like oral cavity, gastrointestinal tract, vagina, and skin of the healthy
individuals as a commensal organism (Kleinegger et al., 1996; Huﬀnagle and Noverr, 2013). Host-
related factors can predispose the transformation of harmless Candida into an opportunistic
pathogen, causing infection or candidiasis in superﬁcial mucous surfaces which can progress
into invasive mycoses (Nett and Andes, 2006). Foregoing factors include, but not limited to
immuno-suppression, prolonged treatment with wide-spectrum antibiotics and chronic diseases
(Kullberg and Arendrup, 2015; Polke et al., 2015). The epidemiology of invasive candidiasis
varies geographically (Morgan, 2005; Pfaller et al., 2011). It signiﬁcantly increases the period
of hospitalization, economic burden and mortality, especially in ICU patients or those under
chemotherapy or with a history of abdominal surgery (Falagas et al., 2006; Berdal et al., 2014;
Drgona et al., 2014).
Only few classes of antifungals such as polyenes, azoles, echinocandins, allylamines, and
ﬂucytosine are available for the treatment of Candida infections (Sanglard et al., 2009).
However, there are various undesirable properties, most importantly the dose-related toxicity
in aforementioned antifungals (Chandrasekar, 2011). Ideally, an antifungal should have null or
reduced toxicity toward human cells (Wong et al., 2014). For instance, amphotericin B is a polyene
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FIGURE 1 | Examples of phenolic compounds and main derivates classified as phenolic acids.
available for systemic administration, but its use has been limited
due to its systemic side eﬀects such as nephrotoxicity (Odds
et al., 2003). Azole antifungals have some side eﬀects associated
with gastrointestinal, hepatic, and endocrinologic disorders and
interfere with oxidative drug metabolism in the liver (Joly et al.,
1992).
In addition, rising drug resistance is an inevitable problem. In
particular, Candida glabrata and Candida krusei show intrinsic
resistance to ﬂuconazole, the drug of choice for AIDS patients
(Kanafani and Perfect, 2008; Siikala et al., 2010; Rautemaa and
Ramage, 2011). Drug resistance has already been reported for
recently introduced echinocandin antifungal agents (Hakki et al.,
2006; Ben-Ami et al., 2011; Clancy andNguyen, 2011; Seneviratne
et al., 2011). Moreover, bioﬁlm mode of Candida is known to be
highly resistant to antifungal agents (Chandra et al., 2005; Niimi
et al., 2010). Therefore, it is necessary to discover new antifungal
agents or safer alternatives to improve the eﬃcacy of treatment
againstCandida infections. In this regard, antifungal agents based
on natural resources, such as phenolic compounds may be an
alternative strategy to negate the rising antifungal drug resistance
(Negri et al., 2014). This review attempts to critically analyze the
possible use of phenolic acids as a therapeutic strategy against
Candida infections.
Phenolic compounds are widely found in plant foods (fruits,
cereal grains, legumes, and vegetables) and beverages (tea, coﬀee,
fruits juices, and cocoa). Themost common phenolic compounds
are phenolic acids (cinnamic and benzoic acids), ﬂavonoids,
proanthocyanidins, coumarins, stilbenes, lignans, and lignins
(Figure 1; Cowan, 1999; Chirinos et al., 2009; Khoddami et al.,
2013). The anti-Candida properties of phenolic compounds that
have been widely reported in the literature include inactivation of
enzyme production (Evensen and Braun, 2009) and anti-bioﬁlm
eﬀect (Evensen and Braun, 2009; Shahzad et al., 2014).
Phenolic acids are derivatives of hydrocinnamic,
hydrobenzoic, phenylacetic, and phenylpropionic acids
(Figures 1 and 2; Pereira et al., 2009; Cueva et al., 2010).
Phenolic acids commonly exist as esters, glycosides or amides
in nature, but not in their free form. The determining factor for
characterization of phenolic acids is the number and the location
of hydroxyl groups on the aromatic ring. Some natural sources
are rich in phenolic acids and shown to possess a promising
action against Candida (Table 1). In this review, we discuss the
anti-candidal activity of the phenolic acid compounds, possible
mechanism of actions and future directions.
ANTIFUNGAL ACTIVITY OF PHENOLIC
ACIDS AGAINST Candida SPECIES
Natural extracts containing phenolic acids have demonstrated
antifungal activity against Candida species (Table 1). Phenolic
acid derivatives isolated from these sources such as gallic, caﬀeic,
cinnamic, benzoic, protocatechuic, and phenylacetic acids also
have antifungal activity (Table 2). However, the antifungal eﬀect
of the natural extracts may vary due to the diﬀerences in
the quantity and the type of phenolic acid. In addition, the
solvents used for extraction may also aﬀect the antifungal eﬀect.
Moreover, other compounds present in natural extracts may
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FIGURE 2 | General chemical structures of the phenolic acids [based on Pereira et al. (2009) and Cueva et al. (2010)].
act synergistically with phenolic acids to enhance the overall
antifungal eﬀect (Pereira et al., 2007; Nowak et al., 2014).
Therefore, phenolic acids derived from diﬀerent natural sources
have highly variable MIC values against Candida (Table 2).
Hence, a clear understanding of the composition of phenolic
acids present in the natural extract is important to assess
its potential as an antifungal agent (Salvador et al., 2004;
Rangkadilok et al., 2012).
The main Candida virulence factors are exoenzymes
production, bioﬁlm formation, adherence, and dimorphism
(Vuong et al., 2004; Netea et al., 2008; Williams et al., 2011).
Few studies have demonstrated the inﬂuence of phenolic acids
against these factors. Anti-bioﬁlm eﬀect of phenolic acids
against Candida sp. was reported (Wang et al., 2009; Alves
et al., 2014; De Vita et al., 2014). However, the studies used only
reference samples or did not cite the tested strain (Table 2). The
anti-bioﬁlm eﬀect of these molecules should be carried out with
clinical isolates in vitro and in vivo, since the ultimate goal of
using these molecules is to treat candidiasis and a wider range
of strains could provide more reliable results. Besides that, it
also has found an inﬂuence of caﬀeic acid derivate against the
Candida dimorphism (Sung and Lee, 2010).
However, several studies described eﬀect onCandida virulence
factors of some others phenolic molecules. For instance,
bisbibenzyl stimulates the synthesis of farnesol, an inhibitor
of hyphae formation, via upregulation of Dpp3 gene (Zhang
et al., 2011). Hence, bisbibenzyl may reduce C. albicans hyphal
formation and aﬀect bioﬁlm formation. Moreover, anti-hyphae
eﬀect in C. albicans was also found following the treatment with
epigallocatechin-gallate (Han, 2007), licochalcone A, gladribin
(Messier and Grenier, 2011), and thymol (Braga et al., 2007).
Additionally, eugenol reduces germ tube formation in C. albicans
(Pinto et al., 2009). Beyond that, several studies have shown anti-
bioﬁlm (Messier et al., 2011; Alves et al., 2014; Rane et al., 2014;
Shahzad et al., 2014) and anti-adhesive (Feldman et al., 2012;
Rane et al., 2014; Shahzad et al., 2014) activities of phenolics
against Candida.
The number of studies on other phenolic molecules on
Candida virulence factors with interesting results inspires a
carefully investigation of phenolic acids inﬂuence on these
factors.
MECHANISM OF ACTION, BIOLOGICAL
PATHWAYS, AND SYNERGISM WITH
ANTIFUNGAL AGENTS OF PHENOLIC
ACIDS AGAINST Candida
In order to obtain some insights on the antifungal activity of
phenolic acids, herein we compare the existing data along the
lines of mechanism of action, synergy with known antifungal
agents and others biological pathways (Figure 3).
Mechanisms of Action and Biological
Pathways
Phenolic acids such as ferulic and gallic acids are known to
aﬀect the cell membrane of Gram-positive and Gram-negative
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TABLE 1 | Phenolic acids derived from plants extracts showing activity against Candida sp.
Plant Phenolic acids found Type of
extract
Microorganism MIC value
µg/ml
MBC value
µg/ml
Reference
Buchenavia tomentosa Gallic acid Aqueous C. albicans ATCC 18804
C. tropicalis ATCC 13803
C. krusei ATCC 6258
C. glabrata ATCC
C. parapsilosis ATCC 22019
C. dubliniensis NCPF 3108
200–12500 6500 C. krusei
(ATCC 6258)
Teodoro et al.,
2015
Rosa rugosa Protocatechuic, gallic, and
p-coumaric acids
Methanolic C. albicans ATCC 10231
C. parapsilosis ATCC 22019
156 1250 Nowak et al.,
2014
Teucrium arduini L. Ferulic acid Ethanolic C. albicans ATCC 10231 4000 NR Kremer et al.,
2013
Potentilla sp. Caffeic acid and ferulic acid Acetonic and
methaolic
C. albicans ATCC 10231 780–1560 NR Wang et al.,
2013
Dimocarpus longan
Lour
Gallic acid Spray-dried or
Freeze-dried
water
C. krusei ATCC 10231
C. parapsilosis ATCC 22019
C. albicans ATCC 90028 and
clinical strains
500–4000 NR Rangkadilok
et al., 2012
Ligusticum mutellina L. Gallic, p-OH-benzoic,
caffeic, p-coumaric, and
ferulic acids
Methanolic C. albicans ATCC 10231
C. parapsilosis ATCC 22019
1250 2500 Sieniawska
et al., 2013
Limonium avei Caffeic, m-coumaric,
p-coumaric, ferulic,
isovanillic,
p-methoxybenzoic,
protocatechuic, sinapinic,
and vanillic acids
Ethanolic C. albicans ATCC 10231 4000 >4000 Nostro et al.,
2012
Kitaibelia vitifolia p-hydroxybenzoic, caffeic,
syringic, p-coumaric, and
ferulic acids
Ethanolic C. albicans ATCC 10231 15.62 NR Maskovic et al.,
2011
Tamarix gallica L. Gallic, synnapic,
p-hydroxybenzoic, syringic,
vanillic, p-coumaric, ferrulic,
trans-2-hydroxycinnamic
and trans-cinnamic acids
Hydromethanolic C. kefyr, C. holmii, C. albicans,
C. sake, C. glabrata
2000 NR Ksouri et al.,
2009
Cirsium sp. Caffeic, p-coumaric, ferulic,
p-hidroxybenzoic,
protocatechuic vanillic, and
gallic acids
Aqueous C. albicans ATCC 10231 780–1560 6250 to
>50000
Nazaruk et al.,
2008
Olea europaea L. Caffeic acid Aqueous C. albicans CECT 1394 5000∗ NR Pereira et al.,
2007
Anogeissus latifolia Gallic acid Hydroalcoholic
after maceration
with ether
Candida albicans (MTCC 183) 7.28 μg/ml NR Govindarajan
et al., 2006
Berry (Cloudberry
Raspberry, Strawberry)
Hydroxycinnamic acids Acetonic 70% Candida albicans NCPF 3179 1000 μg/ml NR Nohynek et al.,
2006
NR, not reported; *IC25.
bacteria leading to a change in cell surface hydrophobicity
and charge, ultimately causing leakage of cytoplasmic content
(Borges et al., 2013). A similar eﬀect has been suggested for
the caﬀeic acid derivative on Candida cytoplasmatic membrane
(Sung and Lee, 2010). Furthermore, a possible eﬀect on the
C. albicans cell wall has been shown for caﬀeic acid derivatives
which may interfere with 1,3-β-glucan synthase (Ma et al.,
2010).
It is noteworthy that polyene antifungals also cause pouring of
cellular contents through direct binding to ergosterol, distorting
the membrane function. Also, azole antifungal agents inhibit
biosynthesis of ergosterol (Vanden Bossche et al., 2004). No study
on the eﬀect of phenolic acid on the ergosterol composition or
biosynthesis could be detected.
Mode of action of several others phenolic compounds
provide some clues to deduce the mechanism of phenolic
acids. For instance, isoquercetin (Yun et al., 2015), curcumin
(Lee and Lee, 2014), and lariciresinol (Pinto et al., 2009) can
damage the C. albicans cell membrane. On the other hand,
eugenol and methyleugenol cause considerable reduction in the
ergosterol biosynthesis in Candida and subsequently aﬀecting
the cell membrane (Ahmad et al., 2010b). Similar eﬀect has
been observed with epigallocatechin-3-gallate (Navarro-Martinez
et al., 2006), thymol and carvacrol (Ahmad et al., 2011). Besides,
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TABLE 2 | Evidences from literature regarding anti-Candida effect of phenolic acids.
Molecule Anti-Candida effect Result found Reference
Gallic acid Planktonic cells of C. albicans (ATCC 18804), C. krusei
(ATCC 6258), C. parapsilosis (ATCC 22019),
C. dubliniensis (NCPF 3108), and C. glabrata (ATCC
90030)
MIC (μg/ml) respectively: 10000, 10000, 10000,
10000, 8
Teodoro et al., 2015
Planktonic cells and biofilm of C. albicans (ATCC
90028), C. glabrata (ATCC 2001), C. parapsilosis
(ATCC 22019), and C. tropicalis (ATCC 750)
MIC (μg/ml) planktonic: <156 μg/ml MIC (μg/ml)
biofilm respectively: 5000, 1250, 625, 625
Alves et al., 2014
Planktonic cells (plate diffusion) MIC (mg cm−3): 2.5 Manayi et al., 2013
Planktonic cells of C. albicans (ATCC 10231) and
C. tropicalis (ATCC 750)
MIC and MFC (μg/ml) respectively: 200, 200, 200, 100 Gehrke et al., 2013
Planktonic cells of C. albicans (ATCC 90028) and 5
clinical strains, C. krusei (ATCC 6258), and
C. parapsilosis (ATCC 20019)
MIC (μg/ml) respectively: 4000,4000,8000,4000,
16000, 16000, 8000, 4000
Rangkadilok et al., 2012
Planktonic cells of C. albicans (ATCC 10231) and
C. parapsilosis (ATCC 22019)
MIC (μg/ml) respectively: 8, 16 Ozcelik et al., 2011
Planktonic cells of C. albicans (ATCC 90028), C. krusei
(ATCC 6258), and C. parapsilosis (ATCC 22019)
MIC (μg/ml): 100 Liu et al., 2009
Biofilm of C. albicans (not cited strain) MIC (μg/ml): 1000 Wang et al., 2009
Planktonic cells of C. albicans (MTCC 183) MIC (μg/ml): 1.78 Govindarajan et al., 2006
Planktonic cells of C. albicans (not cited strain) Halo: 12 mm (100 μg on a sterile filter paper disk with
6 mm diameter)
Fogliani et al., 2005
Caffeic acid Planktonic cells of C. albicans and inhibition of isocitrate
lyase activity assay
MIC (μg/ml): 1000; inhibition of 91,5% of the isocitrate
lyase enzyme activity
Cheah et al., 2014
Planktonic cells and biofilm of C. albicans (ATCC 10231) MIC (μg/ml): planktonic: 128; pre-formed, 4 and 24 h
biofilm: 256
De Vita et al., 2014
Planktonic cells of C. albicans (ATCC 10231) and
C. parapsilosis (ATCC 22019)
MIC (μg/ml) respectively: 8, 16 Ozcelik et al., 2011
Protocatechuic acid Planktonic cells of C. albicans (LMP709U) MIC and MFC (μg/ml) respectively: 156, 312 Kuete et al., 2009
Planktonic cells of C. albicans (10231) and C. tropicalis
(ATCC 7349)
MIC (μg/ml) respectively: 500, 400 Pretto et al., 2004
Phenylacetic acid Planktonic cells (plate diffusion) of C. albicans (clinical
strains)
Halo: 8–10.5 mm (20 μl of a 2000 ng/ml phenylacetic
acid water solution on sterile filter paper disk with 6 mm
diameter)
Mendonca Ade et al., 2009
Cinnamic acid Immunoregulatory effect on monocytes activation
against C. albicans (SC 5314)
Significant reduce of C. albicans counts in 50 and
100 μg/ml
Conti et al., 2013
Planktonic cells of C. albicans (ATCC 90028, ATCC
10231, PYCC 3436T) C. parapsilosis (ATCC 22019,
PYCC 2545), C. glabrata (PYCC 2418T) C. tropicalis
(PYCC 3097T), C. krusei (PYCC 3341), C. lusitaniae
PYCC 2705T and synergism with antifungals
IC 50 (mmol l−1): 0.09 to 0.74; none synergism found Faria et al., 2011
Benzoic acid Planktonic cells of C. albicans (ATCC 90028, ATCC
10231, PYCC 3436T) C. parapsilosis (ATCC 22019,
PYCC 2545), C. glabrata (PYCC 2418T) C. tropicalis
(PYCC 3097T), C. krusei (PYCC 3341), C. lusitaniae
PYCC 2705T and synergism with antifungals
IC 50 (mmol l−1): 0.05–0.73 Synergism found to
C. albicans with amphotericin and itraconazole
Faria et al., 2011
cardanol demonstrated chitin-binding ability in C. albicans cell
wall (Mahata et al., 2014).
Few studies have found about others biological pathways
of phenolic acids against Candida. Exemplifying, an in vitro
immunoregulatory eﬀect on monocytes against C. albicans by
cinnamic acid (Conti et al., 2013) and a inhibition of C. albicans
isocitrate lyase enzyme activity after treatment with caﬀeic acid
(Cheah et al., 2014) was reported. However, several studies
have suggested that the other biological pathways and cellular
targets of others phenolic compounds may be diﬀerent from
that of existing antifungal agents. Some phenolic compounds
have shown to induce apoptotic mechanisms in Candida, thereby
contributing to their antifungal activity (Zore et al., 2011). For
instance, eugenol inhibits the cell cycle at G1, S, and G2-
M phases in C. albicans and consequently induces apoptosis.
Another phenolic compound, curcumin also induces apoptosis
in C. albicans, by increasing the reactive oxygen species (ROS)
and induction of CaMCA1 gene expression (Cao et al., 2009).
On the contrary, baicalein increases ROS causing perturbation
in mitochondrial homeostasis in C. krusei without inducing
apoptosis (Kang et al., 2010). Methyl chavicol seemed to induce
aptotosis in C. albicans although the exact pathway is still not
clear (Khan et al., 2014). Blocking eﬀect of thymol, carvacrol
(Ahmad et al., 2013) and baicalein (Huang et al., 2008) on the
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FIGURE 3 | Described mechanisms of action and biological pathways of some phenolic acids against Candida. (1) Ma et al. (2010); (2) Cheah et al.
(2014); (3,4) Sung and Lee (2010); (5) Conti et al. (2013); (6) Alves et al. (2014); (7) De Vita et al. (2014); (8) Wang et al. (2009).
drug transporter pumps in Candida has been demonstrated using
rhodamine 6G dye. Inhibition of eﬄux transporters results in
accumulation of antifungal compounds inside the cell making
Candida highly susceptible to the antifungal agent (Huang et al.,
2008). These helpful anti-Candida biological pathways observed
for phenolic molecules, mainly on the drug transporters pumps
may contribute to elucidate the possible eﬀects of phenolic acids
against Candida.
Another aspect to be considered is that previous studies
reported that some Candida species were able to metabolize
phenolic acids (Middelhoven et al., 1992; Middelhoven, 1993).
C. parapsilosis was able to grow in the presence of some phenolic
acids after 3 days of cultivation. On the other hand, C. tropicalis
was unable to grow in the presence of phenolic acids even after
14 days of cultivation (Middelhoven, 1993). These evidences
should be better investigated in the future. Further studies are
warranted to obtain a deeper understanding of the mechanism
of action and others biological pathways of phenolic acids on
Candida cells.
Synergism with Existing Antifungal
Agents
Apart from rising antifungal resistance, there are other important
limitations in the existing antifungal agents, such as inadequate
spectrum of activity, poor bioavailability, small tolerance index,
interactions with other drugs, inadequate pharmacokinetic
proﬁle, and considerable toxic eﬀects (Lewis and Graybill,
2008; Pfaller et al., 2010). Although phytochemicals remain
an important source for the discovery of new antifungal
agents, micro-plate based in vitro screening assays have not
shown higher eﬀectiveness of plant extracts when compared
to the existing antifungal agents with higher eﬃcacy (Newman
and Cragg, 2012). Hence, in general, plant extracts with
higher minimum inhibitory concentrations (MICs) such
as 1000 μg/ml are considered ineﬀective (Morales et al.,
2008).
Therefore, some studies have explored the possibility of
synergistic activity of phenolic acids and existing antifungal
agents in order to maximize the antifungal eﬀect. It is
a good strategy to study the synergistic eﬀect when MIC
values of phenolic acids against Candida are highly variable
(Rauha et al., 2000; Kalinowska et al., 2014). Synergistic
eﬀect of benzoic acid with amphotericin B and itraconazole
against C. albicans has been reported in literature (Faria
et al., 2011; Table 3). However, mechanism of this synergistic
eﬀect of phenolic acids and conventional antifungal agents
is poorly understood. Therefore, it is important to examine
similar synergistic eﬀects shown by others phenolic compounds
and conventional antifungal agents in order to obtain some
insight.
A promising synergism between phenolic compounds and
ﬂuconazole against resistant strains of Candida tropicalis was
described recently (da Silva et al., 2014). Several other studies
have also demonstrated a signiﬁcant synergism between other
known antifungals and phenolic compounds against C. albicans
(Table 3). Some studies suggested that the synergism is due to
the induction of apoptosis by an increase in the production
of ROS. Hence, it was found that amphotericin B together
with baicalein or curcumin increases the production of ROS
(Sharma et al., 2010; Fu et al., 2011). A similar eﬀect has
been observed with ﬂuconazole and curcumin (Sharma et al.,
2010).
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TABLE 3 | Synergism of phenolic compounds with traditional antifungals in their action against Candida albicans.
Compound Fluconazole Amphotericin B Itraconazole Others
2,5 Dihydroxybenzaldehyde ___ Faria et al., 2011 Faria et al., 2011 ___
Baicalein Huang et al., 2008† Fu et al., 2011 ___ ___
Benzoic acid∗∗ ___ Faria et al., 2011 Faria et al., 2011 ___
Benzyl benzoate Zore et al., 2011† ___ ___ ___
Butylated hydroxyanisole Simonetti et al., 2002† Andrews et al., 1977∗ ; Beggs et al.,
1978∗
Simonetti et al., 2003†
Carvacrol Ahmad et al., 2013‡ ___ ___ ___
Cinnamaldehyde Khan and Ahmad, 2012 ___ ___ ___
Curcumin I Sharma et al., 2010‡ Sharma et al., 2010 Sharma et al., 2010‡ Sharma et al., 2010‡
Epigallocatechin-gallate Hirasawa and Takada, 2004‡ Hirasawa and Takada, 2004‡ ; Han,
2007
Navarro-Martinez et al.,
2006
Navarro-Martinez et al.,
2006
Eugenol Ahmad et al., 2010a‡ ; Zore et al.,
2011; Khan and Ahmad, 2012∗∗∗
___ ___ ___
Glabridin Liu et al., 2014 ___ ___ Messier and Grenier, 2011
Honokiol Jin et al., 2010† ___ ___ ___
Licochalcone A ___ ___ ___ Messier and Grenier, 2011
Methyleugenol Ahmad et al., 2010a‡ ___ ___ ___
Punicalagin Endo et al., 2010† ___ ___ ___
Propyl gallate D’Auria et al., 2001† Andrews et al., 1977; Beggs et al.,
1978∗
D’Auria et al., 2001† Strippoli et al., 2000†
Thymol Guo et al., 2009‡ ; Faria et al.,
2011; Ahmad et al., 2013‡
Guo et al., 2009; Faria et al., 2011 Faria et al., 2011 ___
∗ Ineffectiveness antifungal effect of phenolic alone; ∗∗phenolic acid; ∗∗∗performed on biofilm formation; †resistant strain; ‡resistant and susceptible strains.
Another hypothesis for the aforementioned synergism is the
association between folic acid cycle and ergosterol biosynthesis
pathways of C. albicans. Hence, epigallocatechin-gallate, a
phenolic compound was demonstrated to have a synergistic
antifungal eﬀect on Candida when combined with itraconazole
or ketoconazole (Navarro-Martinez et al., 2006). Azoles directly
inhibit the ergosterol biosynthesis while epigallocatechin-gallate
has an antifolatic eﬀect that indirectly aﬀects the ergosterol
biosynthesis. Epigallocatechin-gallate causes a depletion of the
enzyme S-adenosylmethionine which in turn aﬀects the enzyme
Sterol C24 methyltransferase. Hence, lower production of C24
methyltransferase negatively aﬀects the ergosterol biosynthesis.
Direct and indirect eﬀects on ergosterol biosynthesis explain the
synergism between epigallocatechin-gallate and azoles (Navarro-
Martinez et al., 2006).
Another study has shown that phenolic compounds such
as thymol and carvacrol signiﬁcantly decrease the expression
levels of virulence genes CDR1 and MDR1 in ﬂuconazole-
resistant C. albicans (Ahmad et al., 2013). An in vivo study
on systemic candidiasis in mice demonstrated that following
the treatment with honokiol and ﬂuconazole, the survival rate
was 100% while a monotherapy showed only a survival rate
of 80% to ﬂuconazole and 20% to honokiol, respectively.
Furthermore, the synergism of these two compounds led to
a notable reduction in C. albicans counts in mouse kidneys
compared with the ﬂuconazole treatment alone (Jin et al.,
2010). Similarly, mice treated with epigallocatechin-gallate and
amphotericin B survived approximately 24 and 30 days longer
when compared to the groups treated only with epigallocatechin-
gallate or amphotericin B, respectively (Han, 2007). Considering
the foregoing evidence obtained for other phenolic compounds,
it is likely that potential of synergism exists between known
antifungal agents and phenolic acids and this possibility needs to
be examined in future.
Safety of the Phenolic Acids In vitro and
In vivo
An ‘ideal’ antifungal agent for Candida infections should not
have side eﬀects or toxicity (Chapman et al., 2008; Wong et al.,
2014). However, in reality, all the antifungals currently in use
have some side eﬀects on gastrointestinal tract, liver and kidney
(Wingard et al., 1999; Bates et al., 2001). Therefore, practically
one would expect to have some dose-related side eﬀects from
any new antifungal agent. It is imperative to understand this
limitation in order to appreciate promising qualities of the drug
under investigation. DNA-damaging eﬀect of phenolic acids has
been observed in p53R cell lines treated with gallic acid (Hossain
et al., 2014). Moreover, in vivo hepatotoxicity was observed in rats
when given a diet supplemented with more than 200 mg/kg/day
of gallic acid (Galati et al., 2006). In addition, hematological
disorders, as well as liver and kidney weight increase were
observed in rats fed with 0.6–5% of gallic acid daily for 13 weeks
(Niho et al., 2001).
A potential carcinogenicity was observed on the fore-stomach
of rats when fed with a powdered diet containing 0.4% of caﬀeic
acid for up to 28 weeks (Hirose et al., 1998). The clastogenic
power of caﬀeic and cinnamic acids have been described in vitro
(Maistro et al., 2011). Subcronic administration of protocatechuic
acid (0.1% in drinking water) for 60 days has shown a possible
liver and kidney toxicity in mice (Nakamura et al., 2001).
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Sodium benzoate and sodium phenylacetate have been used in
the treatment of acute hyperammonaemia and are derived from
benzoic acid and phenylacetic acid respectively. Inappropriate
doses of both substances may cause plasma acidosis, hypotension,
cerebral edema and other neurotoxical eﬀects, sometimes even
death of patients (Kaufman, 1989; Praphanphoj et al., 2000).
Phenylacetic acid can also aﬀect the osteoblastic functions
in vitro and increase cell proliferation in the alveolar region
(Kaufmann et al., 2005; Yano et al., 2007). Sodium and potassium
benzoates could be clastogenic, mutagenic and cytotoxic to
human lymphocytes in vitro (Zengin et al., 2011). Therefore, is
imperative to examine the dose-related toxicity of phenolic acids
in a series of comprehensive in vitro, in vivo and clinical studies
before administration as an antifungal agent.
CONCLUSION
Phenolic acids demonstrate considerable antifungal properties
against Candida. Previous studies have shown phenolic acid
compounds possess considerable anti-adhesion, anti-bioﬁlm
eﬀects, and inhibitory activity on morphogenesis and exoenzyme
production of Candida species. However, hitherto no clear
mechanism of action of phenolic acids on Candida cells
and virulence factors has been described compared to the
existing antifungal agents. Interestingly, there is substantial
evidence of the synergistic eﬀect of phenolic acids and existing
antifungal agents which may become a promising anti-candidal
strategy. However, more studies are in demand for a conclusive
statement regarding their role. Therefore, we propose that
more comprehensive studies are mandatory to obtain evidence
regarding the suitability of the use of phenolic acids as a successful
antifungal agent in future.
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